Garfield Alastair

Chief Scientific OfficerRHYTHM PHARMACEUTICALS, INC. (RYTM) · full profile →Form 4 · filed Aug 17, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$913K
Net Open-Market Flow
-$913K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 13, 2026Sell(S)2K$116.11$233K8K
Aug 13, 2026Sell(S)2K$117.08$182K6K
Aug 13, 2026Sell(S)3K$118.28$402K3K
Aug 13, 2026Sell(S)800$119.17$95K2K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001649904-26-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about RYTM insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001649904-26-000013"
Ask your agent
Use Arkolith to summarize insider buying and selling at RHYTHM PHARMACEUTICALS, INC.
over the last 90 days and cite the filings.